Philips Initiates EUR21.5M AI-Assisted Clinical Studies for Brain and Liver Treatments
Philips leads a EUR21.5 million, four-year SHERPA project launching seven clinical studies at five European centers to validate AI- and robotics-assisted workflows for brain aneurysm and liver tumor treatments. Sixteen organizations, supported by EU Innovative Health Initiative funding and industry in-kind contributions, aim to automate imaging, planning and decision support.
1. Project Launch and Funding
Philips is coordinating the SHERPA consortium with a total budget of EUR21.5 million over four years. The project receives co-funding from the EU Innovative Health Initiative and in-kind contributions from industry partners, forming a 16-member collaboration across seven European countries.
2. AI and Robotics Innovations
The initiative focuses on developing AI-powered algorithms for aneurysm detection, risk prediction, device selection and positioning guidance, as well as robotic assistance for precision in minimally invasive neurovascular and tumor procedures. Automated workflows aim to reduce repetitive tasks and accelerate decision-making for interventional (neuro)radiologists.
3. Clinical Studies Overview
Seven clinical studies will be conducted at University Medical Center Utrecht, St Antonius Hospital, University Medical Center Hamburg-Eppendorf, Hôpital Bicêtre AP-HP and Hospital de la Santa Creu i Sant Pau. These trials will evaluate patient selection, procedural guidance, imaging optimization, treatment success confirmation and remote follow-up solutions.